title: Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
abstract: We reported total correction of blood coagulation plasma factor VIII (FVIII) activity, using adeno-associated virus serotype 8 (AAV8) vectors for liver-specific gene transfer in hemophilia A mice. We now show, irrespective of immunosuppression or route of administration, total long-term correction of hemophilia A mice with pseudotyped AAV8 and AAV9 vectors. We delivered two FVIII vectors, one expressing canine heavy chain and the other expressing canine light chain. Interestingly, when these vectors were given by hepatic portal vein to hemophilia A dogs, only modest FVIII levels were seen despite the species-specific transgene. No dogs treated developed FVIII inhibitors. However, of three dogs treated with AAV8 vector, the single male, given 1.25 x 10(13) genome copies per vector per kilogram (GC/vector/kg), maintained a level of >4.5% for more than 2 years. In contrast, the two female dogs expressed only 2% FVIII activity despite receiving higher doses of 1.52 x 10(13) and 3 x 10(13) GC/vector/kg, respectively. On the other hand, a male dog treated with AAV9 vector at a low dose (6 x 10(12) GC/vector/kg) maintained FVIII levels of 2-2.5% of normal without bleeding for 200 days (observation ongoing). Although hemophilia A mice were not predictive of vector efficacy in dogs, the two treated male dogs became symptom-free for long periods. Even so, translation of these robust vectors either in appropriate large animals or human beings remains challenging.
authors.affiliation: Department of Genetics, University of Pennsylvania, Philadelphia, PA 19104-6145, USA.
authors.forename: Rita
authors.initials: R
authors.lastname: Sarkar
authors.forename: Melinda
authors.initials: M
authors.lastname: Mucci
authors.forename: Sankar
authors.initials: S
authors.lastname: Addya
authors.forename: Renee
authors.initials: R
authors.lastname: Tetreault
authors.forename: Dwight A
authors.initials: DA
authors.lastname: Bellinger
authors.forename: Timothy C
authors.initials: TC
authors.lastname: Nichols
authors.forename: Haig H
authors.initials: HH
authors.lastname: Kazazian
mesh_terms: D000818:Animals; D003520:Cyclophosphamide / Q000008:administration & dosage; D000229:Dependovirus; D004285:Dogs; D005169:Factor VIII / Q000235:genetics* / Q000627:therapeutic use; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006467:Hemophilia A / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008099:Liver / Q000098:blood supply / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011169:Portal Vein; D013997:Time Factors; D019076:Transgenes
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D005169:Factor VIII